Hematopoietic cell transplantation for Langerhans histiocytosis
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e298Keywords:
Treatment Failure, Hematopoietic Stem Cell Transplantation, Histiocytosis, Langerhans-Cel, Transplantation ConditioningAbstract
Langerhans cell histiocytosis is a rare myeloid neoplasm that primarily affects children. Initial treatment depends on risk stratification, but overall survival is excellent. Patient with high-risk disease with risk organ involvement can experience disease reactivation or refractoriness to front-line therapy. A standard approach is not established in the literature, with different reported strategies, including conventional chemotherapy, MAPK-inhibitors and allogeneic hematopoietic (HCT). Allogeneic HCT is supported by retrospective studies with overall survival ranging from 56 to 77% in the largest series. Disease status at the time of HCT and the conditioning regimen (reduced-intensity conditioning versus myeloablative conditioning) correlates with survival and toxicity. Most recently, reduced-intensity conditioning modality has emerged as the preferred option for patients diagnosed with Langerhans cell histiocytosis who require allogeneic HCT.
References
1. Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008;51(1):71–5. https://doi.org/10.1002/pbc.21498 DOI: https://doi.org/10.1002/pbc.21498
2. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. New Eng J Med. 2018;379(9):856–68. https://doi.org/10.1056/nejmra1607548 DOI: https://doi.org/10.1056/NEJMra1607548
3. Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Arch Pediatr. 2019;26(5):301–7. https://doi.org/10.1016/j.arcped.2019.05.015 DOI: https://doi.org/10.1016/j.arcped.2019.05.015
4. Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14. https://doi.org/10.1182/blood-2012-09-455774 DOI: https://doi.org/10.1182/blood-2012-09-455774
5. Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study. Blood. 2015;126(12):1415–23. https://doi.org/10.1182/blood-2015-03-635151 DOI: https://doi.org/10.1182/blood-2015-03-635151
6. Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34(25):3023–30. https://doi.org/10.1200/jco.2015.65.9508 DOI: https://doi.org/10.1200/JCO.2015.65.9508
7. Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, Russo M, Hargrave D. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7(15):3806–15. https://doi.org/10.1182/bloodadvances.2022008414 DOI: https://doi.org/10.1182/bloodadvances.2022008414
8. Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, Kabbara N, Barkaoui M, Miron J, Chalard F, Milne P, Haroche J, Cohen F, Hélias-Rodzewicz Z, Simon N, Jehanne M, Kolenova A, Pagnier A, Aladjidi N, Schneider P, Plat G, Lutun A, Sonntagbauer A, Lehrnbecher T, Ferster A, Efremova V, Ahlmann M, Blanc L, Nicholson J, Lambilliote A, Boudiaf H, Lissat A, Svojgr K, Bernard F, Elitzur S, Golan M, Evseev D, Maschan M, Idbaih A, Slater O, Minkov M, Taly V, Collin M, Alvarez JC, Emile JF, Héritier S. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37(31):2857–65. https://doi.org/10.1200/jco.19.00456 DOI: https://doi.org/10.1200/JCO.19.00456
9. Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, Baidildina D, Popov A, Zhogov V, Semchenkova A, Litvin E, Kotskaya N, Cherniak E, Voronin K, Burtsev E, Bronin G, Vlasova I, Purbueva B, Fink O, Pristanskova E, Dzhukaeva I, Erega E, Novichkova G, Maschan A, Maschan M. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH. Blood Adv. 2023;7(18):5246–57. https://doi.org/10.1182/bloodadvances.2022009067 DOI: https://doi.org/10.1182/bloodadvances.2022009067
10. Meng G, Feng S, Wang Y. Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children. Front Immunol. 2025;16:1345855. https://doi.org/10.3389/fimmu.2025.1345855 DOI: https://doi.org/10.3389/fimmu.2025.1345855
11. Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E, Holter W, Vormoor J, Wawer A, Ouachee M, Woessmann W, Gadner H. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36(3):215–25. https://doi.org/10.1038/sj.bmt.1705015 DOI: https://doi.org/10.1038/sj.bmt.1705015
12. Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jürgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel G, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning. Br J Haematol. 2015;169(5):711–8. https://doi.org/10.1111/bjh.13347 DOI: https://doi.org/10.1111/bjh.13347
13. Kudo K, Maeda M, Suzuki N, Kanegane H, Ohga S, Ishii E, Shioda Y, Imamura T, Imashuku S, Tsunematsu Y, Endo M, Shimada A, Koga Y, Hashii Y, Noguchi M, Inoue M, Tabuchi K, Morimoto A; Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. Int J Hematol. 2020;111(1):137–48. https://doi.org/10.1007/s12185-019-02760-5 DOI: https://doi.org/10.1007/s12185-019-02760-5
14. Akkari V, Donadieu J, Piguet C, Bordigoni P, Michel G, Blanche S, Casanova JL, Thomas C, Vilmer E, Fischer A, Bertrand Y; French Langerhans Cell Study Group. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003;31(12):1097–103. https://doi.org/10.1038/sj.bmt.1704065 DOI: https://doi.org/10.1038/sj.bmt.1704065
15. Nr E, Kinderkrebsforschung SA. LCH-IV International Collaborative Treatment protocol for children and adolescents with Langerhans cell histiocytosis international sponsor. Available from: http://www.histiocytesociety.org
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Gabriele Zamperlini Netto, Ana Paula Kuczynski Pedro Bom
This work is licensed under a Creative Commons Attribution 4.0 International License.
